Skip to main content
Annals of Intensive Care
Fig. 1 | Annals of Intensive Care

Fig. 1

From: Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial

Fig. 1

CYT107 increases absolute lymphocyte counts and both CD4+ and CD8+ T lymphocytes. Patients’ peripheral blood was analyzed at day 0, 7, 15, 22, 29 (or hospital discharge) and day 90. Data are represented in median and interquartile. Patients who received CYT107 are represented in red. Patients who received placebo are represented in blue. A Median absolute lymphocyte counts: The absolute lymphocyte counts were higher in patients treated with CYT107 versus placebo; *p = 0.005. B and C represents the median CD4+ and CD8+ T cells count for each group, respectively, as obtained by flow cytometry. Both CD4+ and CD8+ T cell counts were significantly higher in the CYT107- versus placebo-treated group after day seven, *(p < 0.005). D HLA-DR expression on CD14+ monocytes was measured by flow cytometry and was indicated in median number of antibodies bound per cell (Ab/cell)

Back to article page